Markel Group (MKL) Q3 2026 earnings summary

Executive summary

• Q3 operating revenue rose 6% to $4.16B from $3.93B YoY; adjusted operating income increased 14% to $707.4M from $621.0M.

• Net income to common shareholders fell to $259.3M from $751.3M as Q3 net investment losses were $280.9M versus $432.9M of gains a year earlier.

• Insurance underwriting improved; Industrial, Financial, and Consumer and Other posted higher Q3 adjusted operating income.

Financial highlights

• Nine-month operating revenue rose to $11.73B from $11.51B; adjusted operating income was $1.64B versus $1.68B.

• Q3 diluted EPS was $18.15 versus $59.25; nine-month diluted EPS was $91.90 versus $120.60.

• Nine-month net income to common shareholders was $1.22B versus $1.50B; comprehensive income to shareholders was $604.6M versus $2.01B.

• Net investment income increased to $258.1M in Q3 from $245.7M and to $770.1M for nine months from $712.8M.

• Reported operating income was $383M in Q3 versus $1.01B and $1.67B for nine months versus $2.40B.

Outlook and guidance

• Global Reinsurance premiums are expected to continue earning over the next two years, with related loss reserves taking several additional years to run off.

• Enstar adverse development cover is subject to approvals and customary conditions, expected to close in Q4 2026, with an immaterial Q4 underwriting-results impact expected.

• Rates were relatively flat across the portfolio through 9M 2026; growth is targeted where pricing is considered adequate.

• Management emphasized long-term value compounding through disciplined underwriting, patient reinvestment, and capital deployment toward opportunities expected to create long-term value.